https://www.nytimes.com/live/2021/10/01/world/covid-delta-variant-vaccines#merck-antiviral-pill-covid Merck’s experimental oral Covid-19 antiviral drug, molnupiravir.Credit... Merck The drug maker Merck said on Friday that it would seek authorization for the first antiviral pill for Covid after its drug, known as molnupiravir, was shown in a clinical trial to cut the risk of hospitalization or death in half when given to high-risk people early in their infections. The treatment could become the first in a wave of antiviral pill products, which experts say could offer a powerful new tool in efforts to tame the pandemic, as they could reach more people than the antibody treatments that are being widely used in the United States for similar patients. “I think it will translate into many thousands of lives being saved worldwide, where there’s less access to monoclonal antibodies, and in this country, too,” said Dr. Robert Shafer,an infectious disease specialist and expert on antiviral therapy at Stanford University. Late-stage study results of two other antiviral pills, one developed by Pfizer and the other by Atea Pharmaceuticals and Roche, are expected within the next few months. The Merck drug, which is designed to stop the coronavirus from replicating, is to be taken as four capsules twice a day for five days. Merck said an independent board of experts monitoring its study data had recommended that its trial be stopped early because the drug’s benefit to patients had proved so convincing. The company said that the Food and Drug Administration had agreed with that decision. For the research, the monitors looked at data through early August, when the study had enrolled 775 volunteers in the United States and overseas. For volunteers who received the drug, their risk of being hospitalized or dying fell 50 percent, without any concerning side effects, compared with those who received placebo pills, Merck said in a news release announcing the findings. Seven percent of volunteers in the group that received the drug were hospitalized, and none of them died, compared with a 14 percent rate of hospitalization and death — including eight deaths — in the group that received the placebo. The Merck pill’s efficacy was lower than that of monoclonal antibody treatments, which mimic antibodies that the immune system generates naturally when fighting the virus. Those drugs have been in high demandrecently, but they are expensive, are typically given intravenously, and have proved cumbersome and labor-intensive for hospitals and clinics to administer. Studies have shown that they reduce hospitalizations and deaths 70 to 85 percent in similar high-risk Covid patients.
At the moment, the company expects to produce 10 million courses of the drug before the end of 2021 alone, which could bring in revenue up to $7 billion. This would make it, in only a few weeks, one of the 10 most lucrative drugs ever. 其它药得加油啊，不然市场都被merck占光了
For volunteers who received the drug, their risk of being hospitalized or dying fell 50 percent, without any concerning side effects, compared with those who received placebo pills. 看起来非常好👍
For volunteers who received the drug, their risk of being hospitalized or dying fell 50 percent, without any concerning side effects, compared with those who received placebo pills. 看起来非常好👍 点苍鹤云 发表于 2021-10-01 07:47
太好了，希望年底能easily accessible, 明年上半年恢复正常生活。小棕丸是第一个做出来的，不会是唯一的一个，也不一定是最好的一个，还可以观望一下以后的几个。相对疫苗，这些口服药受变种的影响比较小，而且越早吃上越有效 Additionally, based on the participants with available viral sequencing data (approximately 40% of participants), molnupiravir demonstrated consistent efficacy across viral variants Gamma, Delta, and Mu. 记得mu是可以逃逸疫苗的 现在药厂还在做prevention trial, 一人得病，全家吃药预防。再认真带一阵子口罩，不能挂在解放前
新闻的感觉是30天内有死的。 Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck. 不过merck自己的好像又没有死的，回头文章出来再看看 KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo. At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), recruitment into the study is being stopped early due to these positive results. Merck plans to submit an application for Emergency Use Authorization (EUA) to the U.S. FDA as soon as possible based on these findings and plans to submit marketing applications to other regulatory bodies worldwide.
原来还对这个药挺报希望的，后来发现它的机理是迫使病毒复制产生巨多错误，从而破坏复制，那问题来了，复制错的病毒有没有危险？对人类正常复制有没有扰乱作用？看过文章做trial的男性被告知不要有sex估计是防止传播风险（这个文章看过找不到了） “They work by interfering with the virus’s ability to replicate in human cells. In the case of molnupiravir, the enzyme that copies the viral genetic material is forced to make so many mistakes that the virus can’t reproduce. That, in turn, reduces a patient’s viral load, shortening infection time and preventing the kind of dangerous immune response that can cause serious illness or death.” https://www.nbcnews.com/health/health-news/daily-pill-treat-covid-could-be-just-months-away-scientists-n1279938
原来还对这个药挺报希望的，后来发现它的机理是迫使病毒复制产生巨多错误，从而破坏复制，那问题来了，复制错的病毒有没有危险？对人类正常复制有没有扰乱作用？看过文章做trial的男性被告知不要有sex估计是防止传播风险（这个文章看过找不到了） “They work by interfering with the virus’s ability to replicate in human cells. In the case of molnupiravir, the enzyme that copies the viral genetic material is forced to make so many mistakes that the virus can’t reproduce. That, in turn, reduces a patient’s viral load, shortening infection time and preventing the kind of dangerous immune response that can cause serious illness or death.” https://www.nbcnews.com/health/health-news/daily-pill-treat-covid-could-be-just-months-away-scientists-n1279938 Seeking668 发表于 2021-10-01 10:44
原来还对这个药挺报希望的，后来发现它的机理是迫使病毒复制产生巨多错误，从而破坏复制，那问题来了，复制错的病毒有没有危险？对人类正常复制有没有扰乱作用？看过文章做trial的男性被告知不要有sex估计是防止传播风险（这个文章看过找不到了） “They work by interfering with the virus’s ability to replicate in human cells. In the case of molnupiravir, the enzyme that copies the viral genetic material is forced to make so many mistakes that the virus can’t reproduce. That, in turn, reduces a patient’s viral load, shortening infection time and preventing the kind of dangerous immune response that can cause serious illness or death.” https://www.nbcnews.com/health/health-news/daily-pill-treat-covid-could-be-just-months-away-scientists-n1279938 Seeking668 发表于 2021-10-01 10:44
Merck has said data shows molnupiravir is not capable of inducing genetic changes in human cells, but men enrolled in its trials had to abstain from heterosexual intercourse or agree to use contraception. Women of child-bearing age in the study could be pregnant and also had to use birth control. The company has a U.S. government contract to supply 1.7 million courses of molnupiravir at a price of $700 per course. 好像卖的不便宜啊
Merck The drug maker Merck said on Friday that it would seek authorization for the first antiviral pill for Covid after its drug, known as molnupiravir, was shown in a clinical trial to cut the risk of hospitalization or death in half when given to high-risk people early in their infections. The treatment could become the first in a wave of antiviral pill products, which experts say could offer a powerful new tool in efforts to tame the pandemic, as they could reach more people than the antibody treatments that are being widely used in the United States for similar patients. “I think it will translate into many thousands of lives being saved worldwide, where there’s less access to monoclonal antibodies, and in this country, too,” said Dr. Robert Shafer, an infectious disease specialist and expert on antiviral therapy at Stanford University. Late-stage study results of two other antiviral pills, one developed by Pfizer and the other by Atea Pharmaceuticals and Roche, are expected within the next few months. The Merck drug, which is designed to stop the coronavirus from replicating, is to be taken as four capsules twice a day for five days. Merck said an independent board of experts monitoring its study data had recommended that its trial be stopped early because the drug’s benefit to patients had proved so convincing. The company said that the Food and Drug Administration had agreed with that decision. For the research, the monitors looked at data through early August, when the study had enrolled 775 volunteers in the United States and overseas. For volunteers who received the drug, their risk of being hospitalized or dying fell 50 percent, without any concerning side effects, compared with those who received placebo pills, Merck said in a news release announcing the findings. Seven percent of volunteers in the group that received the drug were hospitalized, and none of them died, compared with a 14 percent rate of hospitalization and death — including eight deaths — in the group that received the placebo. The Merck pill’s efficacy was lower than that of monoclonal antibody treatments, which mimic antibodies that the immune system generates naturally when fighting the virus. Those drugs have been in high demandrecently, but they are expensive, are typically given intravenously, and have proved cumbersome and labor-intensive for hospitals and clinics to administer. Studies have shown that they reduce hospitalizations and deaths 70 to 85 percent in similar high-risk Covid patients.
🔥 最新回帖
你每天追着人家说别人离没离开有啥意思？离开了不能回来么。。。要说他人没道理就从科学本身来反驳，境界高一点行不行
神牛💩才最有效。建议都不要打疫苗吃药了，一日三顿天天服用才有效
印度神药不是牛那个擦全身？美国海关禁止印度乘客携带进关，所以美国控制不下去，多么强悍的证明啊🤣
前统领几个月前rally的时候劝他们打疫苗，也是嘘声一片啊，川普如果说话不再投合他们的信仰，分分钟被推翻踩几脚，他最不可饶恕的是为了选票把这群被时代遗弃的人的声音凝合在一起，放出来了，后果大家一起消受。
其它药得加油啊，不然市场都被merck占光了
🛋️ 沙发板凳
死亡降低得还要低,吃药是零死亡,吃安慰剂死了8个。
都是命啊！分到药的就活下来了。
好像不是的，服药30天内有人死亡的，但死亡人数比例只有安慰组的一半多，属于效果好，但没有100%。新闻链接补上： https://apnews.com/article/merck-says-experimental-covid-pill-cuts-worst-effects-a9a2245fdcee324f6bbd776a0fffcc60
你把古老的阿昔洛韦给忘了
需要处方吗？
这个结果的意义非同寻常，因为面对delta的高病毒载量和高传染性，疫苗接种过一段时间之后随着抗体水平的下降，就很难阻断所有的感染了。即使打了第三针，时间久了也是一样。疫苗能不能降低被感染的概率和降低breakthrough case的传染性？确实可以，但是delta的传染性实在太高了，面对一个R0高达10的烈性传染病，通过接种疫苗达到群体免疫来保护弱势群体，即使能做到也是短期的。疫苗防止重症需要接种者本身有良好的免疫反应，能够形成生发中心分化出足够的记忆T细胞、记忆B细胞和长寿命浆细胞，而很多老人和免疫受损的人群是做不到这一点的，偏偏这些人也正是新冠感染的高危人群。所以说，一个能够大批生产和大范围推广的小分子药物对于整个社会恢复正常是非常重要的，整体成本要远远小于每年大规模强制接种一次疫苗。
目前美国政府只买了170万剂molnupiravir，Merck说今年年底之前能够生产出1000万剂左右。和单抗比起来，小分子药物大规模生产的障碍要小得多。
cnbc.com/2021/10/01/merck-to-seek-emergency-authorization-for-oral-covid-19-treatment.html
另外从Molnupiravir的实验也可以看出为什么那个horse dewormer神药ivermectin不靠谱，抑制病毒的体外指标叫做IC50，越低越好。Molnupiravir的这个数值是0.14 uM，著名的“人民的希望”是0.49 uM，然后Molnupiravir的给药浓度是每天两次每次800 mg，“人民的希望”remdesivir更是只能靠每天静脉注射才能达到足够的抗病毒浓度。ivermectin的IC 50是Molnupiravir的十几倍，大概是2-3 uM，由于安全性的限制，给药剂量还远远小于Molnupiravir，这个剂量根本无法达到具有临床意义的抗病毒效果。
一般来说，真正有效的药物一个power足够的大规模临床试验就能做出结果来。拿着一大堆真真假假的小规模试验和回顾分析充数，还要掺杂着各种意识形态和阴谋论的所谓早期治疗，没一个靠谱。
没什么比这个药厂再无耻透顶的了。
无用却害人的疫苗赚了多少命钱，多少人不可逆转的疫苗伤害，能不能避免破产，拭目以待。
这个药降低50%的重症率是来自几百人使用后的结果，所以先不要盲目乐观。可能最好就像tamiflu一样。
Additionally, based on the participants with available viral sequencing data (approximately 40% of participants), molnupiravir demonstrated consistent efficacy across viral variants Gamma, Delta, and Mu. 记得mu是可以逃逸疫苗的
现在药厂还在做prevention trial, 一人得病，全家吃药预防。再认真带一阵子口罩，不能挂在解放前
哦，是是是，这个新药和你们的兽药伊维菌素都是Merck生产的，所以里面的成分是一样一样一样的。你们川粉继续在家吃兽药就好了嘛，再被带走个几十万你们GOP就正式变成万年在野党了，挺好的
新闻的感觉是30天内有死的。
Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck.
不过merck自己的好像又没有死的，回头文章出来再看看 KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 MOVe-OUT trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. At the interim analysis, molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012. Through Day 29, no deaths were reported in patients who received molnupiravir, as compared to 8 deaths in patients who received placebo. At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), recruitment into the study is being stopped early due to these positive results. Merck plans to submit an application for Emergency Use Authorization (EUA) to the U.S. FDA as soon as possible based on these findings and plans to submit marketing applications to other regulatory bodies worldwide.
pfizer也在做，机理不一样，protease inhibitor.
mutagenesis的意思是导致人的突变吧？
没事，你这么世人皆醉我独醒，以后染上了继续吃你的动物药就好了。千万别被这些药厂的糖衣炮弹给打中了。
What goes around comes around!
楼上的这家药厂怎么得罪你了，你不喜欢不吃就是了，干嘛这么恶毒呢
不是，这个是指病毒产生突变，产生新变种，具有抗药性
所有抗病毒药都有这个问题/可能性，那也不至于不用药
棒棒的👍🏻
谢谢浣熊MM科普，太好了！
不是， mutagenic可能会致癌
“They work by interfering with the virus’s ability to replicate in human cells. In the case of molnupiravir, the enzyme that copies the viral genetic material is forced to make so many mistakes that the virus can’t reproduce. That, in turn, reduces a patient’s viral load, shortening infection time and preventing the kind of dangerous immune response that can cause serious illness or death.”
https://www.nbcnews.com/health/health-news/daily-pill-treat-covid-could-be-just-months-away-scientists-n1279938
当然最好不要吃，但真得了新冠吃个四五天不至于对人影响太大。 一般癌症都需要一定时间的积累
相比起来，那些个protease inhibitor如果做出来了应该更安全。可以等等pfizer那个efficacy咋样。
毕竟现在啥也没有，这个是第一个做出来的，有药总比没有好， 体内病毒复制太多也容易有后遗症。以后肯定还有更好的
反正觉得这个molnupiravir比ivm的风险大无数倍，而且和疫苗一样风险是长期的，但美国就是不做ivm抗covid的正式trial给个定论和FDA申请，只会冷嘲热讽的无厘头打压，对药厂没利益啊，奈何
抗病毒的药一直都有啊
抗病毒的药当然有，比如得了shingles吃的那个。
怎么预防？我现在都绝望了。大人也就算了。小小娃不可能关在家里一辈子。只要把小娃放出去，基本就是等着他感染了，只是迟或者早的问题。
你可以拒绝打疫苗，万一不小心染上新冠，千万拒绝服用Merck的新药。相信大家都没意见，我们支持你！
ivm背后没有资本的支持，反而有打压，估计最后也就这么糊里糊涂的了。
支持
antibiotics是fight for bacterial infection, antivirals 就是fight for viral infection的呀，哪个医生说没有抗病毒的药啊,莫非你们觉得被virus感染都是靠自己好起来的吗？
The company has a U.S. government contract to supply 1.7 million courses of molnupiravir at a price of $700 per course.
好像卖的不便宜啊
这个机理太牛了 希望有需要的多多服用了只好
是的
true
这是抑制病毒RNA聚合酶的广谱抗病毒药。是最能抗病毒突变的。
可见你的医生也是一知半解。只要病毒在传播复制就一直在突变，有效阻断传播链，减小感染人群，才能最大限度抑制突变。针对进化上最保守的RNA聚合途径的药反而是最广谱最抗突变的。
ivermectin 应该副作用比这个小吧。
病毒当然一直在变异，问题是这个药是不是会加速变异，增加变异。
已经说了，这个药是target进化上最保守的RNA聚合酶通路的。以不变应万变。
难道不是吗？得了flu去看医生，医生就让回家多喝水和吃泰诺。
flu有tamiflu嘛，只不过flu伤害性小，所以risk-benefit一看普通人不需要吃药
有的人其实不需要疫苗也不需要服抗病毒药的。不过他们需要吃其他方面的药。
哎？那为啥伟大的社会主义国家和诸多第三世界国家也不做这种利国利民的trial? 社会主义国家自己没有case 也可以送去第三世界小弟家收买人心。还有印度之前不是用过一段时间后来也停了？都是因为这些国家的领导收了药厂的钱吗？那么个大药厂还不知道谁能先出结果的情况下，到底哪个雷锋送的钱呢？
为啥这么多出来给人洗脑Merck 的和还有辉瑞的新药就是ivermectin 改名了？ 当大家都是傻子吗
外国的trials多得很，但美国没有在美国就不能用 这么多trials和papers，很多国家在用，美国欠所有纳税人一个严格的trial，证明无用不挺好吗，大家就老老实实打疫苗和吃贵的药啦，也不用医疗代言们费劲用马药来吓阻了，lol
这里有trials的列表： https://c19ivermectin.com/
连日本都有医生在试了。
https://twitter.com/SabinehazanMD/status/1443589488869998593
美国医疗资本最恶心了，不是整天吹science吗，那做trial用science证明ivm没用啊，而不是马药马药的像个痞子 前一阵子参院听一个美国医生关于ivm有效的testimony，chair说要责成CDC/NIH做trial给结果，结果也没消息了，资本为了利润什么坏事都干得出来
我觉得来得及。破烂疫苗都炒到400多呢。
科学家告诉你，根据沙子分子结构判定，沙子没营养，你们是不是要求营养学家一定要反复做沙子能吃的trials， 不大规模做沙子能吃的trials就是反科学，这么便宜的东西不做能吃的trials就下结论不能吃，一定是背后有资本， 是资本为了利润什么坏事都干得出来，阻止你吃沙子，一定要卖土豆，小麦给你吃。
让反对疫苗反对新药反对口罩的让自然来决定生死吧。
你们两个真有意思，互相喷之前是不是做点研究呢？人家NIH其实有个关于兽药的trial，4月份就开始了
https://www.nih.gov/news-events/news-releases/large-clinical-trial-study-repurposed-drugs-treat-covid-19-symptoms
一直不肯加ivm呢，8月才加上
终于看到美国的官方IVM trial，看来是参院听证会推动的结果，好事，那些无脑嘲笑ivm马药的可以休矣，期待结果~
还是有些人有concern, 因为它招发病10天以内的人，每天一剂只吃3天。这种治疗的药都是越早吃越有效，晚期就效果小了
merck那个实验是发病5天以内，每天两剂吃5天，这样可能效果比较好
不过好在active-6要招很多人，希望能给ivm做出个像样的结果。估计这里面的fluvoximine也会显著的
加拿大的TOGETHER trial已经给兽药判死刑了。相比起来这个NIH trial剂量更小，发病都10天了还能参加，肯定做不出结果来。
没办法，没有亲妈设计实验，就是很容易做死的
Great!!!!!
你有本事别打疫苗别吃药，自然感染自然淘汰就好，别说一套做一套的。
支持IVM的也有医生啊，也有科学家啊。为什么他们就不可信呢？
不接受疫苗不接受药物的人，别占用医疗资源。
因为它们希望美国越来越糟 永远从疫情里走不出来
靠。这个点又哭着喊着看science。 真是奇葩。 畜牲不打疫苗嘛，就不看science，天天喊别人作弊。 畜牲要吃马药嘛，天天喊着要做实验，要看science。 反正，你正反都有理。可能，你的智商是500。要science是左脑，不要science是右脑。 每次只用一半，典型的250。